1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
GlobeNewswire
GlobeNewswire
Articles 

Adamas Announces New Employment Inducement Grant

February 08, 2019 | About:

EMERYVILLE, Calif., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 50,500 shares of the company’s common stock, at a per share exercise price of $8.96, the closing trading price on February 7, 2019, and restricted stock units to acquire 9,300 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. The Company also continues to deliver on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contact:
Sarah Mathieson
VP, Corporate Communications
510-450-3528
[email protected]


Rating: 0.0/5 (0 votes)

Comments

barruslaurel
Barruslaurel - 1 week ago    Report SPAM

I was diagnosed with Parkinson's disease nearly 4 years ago, at age 51. I had a stooped posture, tremors, muscle stiffness, sleeplessness, and slow movement. I was placed on Sinemet for 7 months and then Sifrol and rotigotine were introduced which replaced the Sinemet but I had to stop due to side effects. I was in denial for a while as there is no history of PD in my family. I also used amantadine, and physical therapy to strengthen muscles all failed. I decided to adopt a more natural approach and started on Parkinson's Herbal formula from Organic Herbal Clinic, the Parkinson's natural formula immensely helped my condition, i had a total recovery from PD with this natural herbal formula treatment. Organic Herbal Clinic official web site www . organicherbalclinic . com. I feel alive again!!

Please leave your comment:


Performances of the stocks mentioned by GlobeNewswire


User Generated Screeners


DANGORDONPE<16
DANGORDONROE ROC 10YR
DANGORDONROC10YR
DANGORDONROE10YR
Praveen ChawlaDividend Achievers
hiroller8Super Stocks
DBrizanCDN2019feb17
curtisAsia xJxCNxIN
awilkinsonLynch
daleromanHigh Margin pe<15
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK